Cargando…

Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy

BACKGROUND: Patients with late‐life depression may be at the preclinical stage of dementia. However, the neurodegenerative processes in late‐life depression are poorly understood. This study aimed to investigate the distribution patterns of amyloid pathology and neurodegeneration in a depressive pop...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Kuan‐Yi, Lin, Kun‐Ju, Chen, Chia‐Hsiang, Chen, Cheng‐Sheng, Liu, Chia‐Yih, Huang, Sheng‐Yao, Yen, Tzu‐Chen, Hsiao, Ing‐Tsung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043710/
https://www.ncbi.nlm.nih.gov/pubmed/29927088
http://dx.doi.org/10.1002/brb3.1016
_version_ 1783339339291295744
author Wu, Kuan‐Yi
Lin, Kun‐Ju
Chen, Chia‐Hsiang
Chen, Cheng‐Sheng
Liu, Chia‐Yih
Huang, Sheng‐Yao
Yen, Tzu‐Chen
Hsiao, Ing‐Tsung
author_facet Wu, Kuan‐Yi
Lin, Kun‐Ju
Chen, Chia‐Hsiang
Chen, Cheng‐Sheng
Liu, Chia‐Yih
Huang, Sheng‐Yao
Yen, Tzu‐Chen
Hsiao, Ing‐Tsung
author_sort Wu, Kuan‐Yi
collection PubMed
description BACKGROUND: Patients with late‐life depression may be at the preclinical stage of dementia. However, the neurodegenerative processes in late‐life depression are poorly understood. This study aimed to investigate the distribution patterns of amyloid pathology and neurodegeneration in a depressive population without dementia. METHODS: The study recruited 63 middle‐aged and elderly patients with major depressive disorder (MDD) and 22 control subjects. The MDD patients were further subdivided into those with mild cognitive impairment (MCI) (n = 24) and non‐MCI (n = 39) patients. We used the global standardized uptake value ratio of (18)F‐florbetapir (AV‐45/Amyvid) positron emission tomography imaging as a biomarker of cerebral amyloidosis and the hippocampal volume as a biomarker for neurodegeneration. Cutoff points of brain amyloid positivity and hippocampal atrophy were determined using independent data obtained from clinically diagnosed Alzheimer's disease (AD) patients in a previous study. RESULTS: Most of the control subjects (81.8%) were biomarker‐negative, in contrast to the MCI MDD patients (37.5%). A relatively high proportion of the MCI MDD patients (12.5%) exhibited both amyloid positivity and hippocampal atrophy as compared to the control subjects (4.5%) and non‐MCI patients (5.1%). However, a considerable proportion of the MCI MDD patients (29.2%) were categorized into the group with hippocampal atrophy alone, and negative amyloid deposition, as compared to the control subjects (0%) and non‐MCI patients (5.1%). CONCLUSIONS: This study highlights the expected heterogeneity of the processes of neurodegeneration in MDD patients. The diverse neurodegenerative processes may have important etiologic and therapeutic implications regarding neurodegenerative pathophysiology in late‐life depression.
format Online
Article
Text
id pubmed-6043710
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60437102018-07-15 Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy Wu, Kuan‐Yi Lin, Kun‐Ju Chen, Chia‐Hsiang Chen, Cheng‐Sheng Liu, Chia‐Yih Huang, Sheng‐Yao Yen, Tzu‐Chen Hsiao, Ing‐Tsung Brain Behav Original Research BACKGROUND: Patients with late‐life depression may be at the preclinical stage of dementia. However, the neurodegenerative processes in late‐life depression are poorly understood. This study aimed to investigate the distribution patterns of amyloid pathology and neurodegeneration in a depressive population without dementia. METHODS: The study recruited 63 middle‐aged and elderly patients with major depressive disorder (MDD) and 22 control subjects. The MDD patients were further subdivided into those with mild cognitive impairment (MCI) (n = 24) and non‐MCI (n = 39) patients. We used the global standardized uptake value ratio of (18)F‐florbetapir (AV‐45/Amyvid) positron emission tomography imaging as a biomarker of cerebral amyloidosis and the hippocampal volume as a biomarker for neurodegeneration. Cutoff points of brain amyloid positivity and hippocampal atrophy were determined using independent data obtained from clinically diagnosed Alzheimer's disease (AD) patients in a previous study. RESULTS: Most of the control subjects (81.8%) were biomarker‐negative, in contrast to the MCI MDD patients (37.5%). A relatively high proportion of the MCI MDD patients (12.5%) exhibited both amyloid positivity and hippocampal atrophy as compared to the control subjects (4.5%) and non‐MCI patients (5.1%). However, a considerable proportion of the MCI MDD patients (29.2%) were categorized into the group with hippocampal atrophy alone, and negative amyloid deposition, as compared to the control subjects (0%) and non‐MCI patients (5.1%). CONCLUSIONS: This study highlights the expected heterogeneity of the processes of neurodegeneration in MDD patients. The diverse neurodegenerative processes may have important etiologic and therapeutic implications regarding neurodegenerative pathophysiology in late‐life depression. John Wiley and Sons Inc. 2018-06-21 /pmc/articles/PMC6043710/ /pubmed/29927088 http://dx.doi.org/10.1002/brb3.1016 Text en © 2018 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Wu, Kuan‐Yi
Lin, Kun‐Ju
Chen, Chia‐Hsiang
Chen, Cheng‐Sheng
Liu, Chia‐Yih
Huang, Sheng‐Yao
Yen, Tzu‐Chen
Hsiao, Ing‐Tsung
Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy
title Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy
title_full Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy
title_fullStr Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy
title_full_unstemmed Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy
title_short Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy
title_sort diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: evidence of cerebral amyloidosis and hippocampal atrophy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043710/
https://www.ncbi.nlm.nih.gov/pubmed/29927088
http://dx.doi.org/10.1002/brb3.1016
work_keys_str_mv AT wukuanyi diversityofneurodegenerativepathophysiologyinnondementedpatientswithmajordepressivedisorderevidenceofcerebralamyloidosisandhippocampalatrophy
AT linkunju diversityofneurodegenerativepathophysiologyinnondementedpatientswithmajordepressivedisorderevidenceofcerebralamyloidosisandhippocampalatrophy
AT chenchiahsiang diversityofneurodegenerativepathophysiologyinnondementedpatientswithmajordepressivedisorderevidenceofcerebralamyloidosisandhippocampalatrophy
AT chenchengsheng diversityofneurodegenerativepathophysiologyinnondementedpatientswithmajordepressivedisorderevidenceofcerebralamyloidosisandhippocampalatrophy
AT liuchiayih diversityofneurodegenerativepathophysiologyinnondementedpatientswithmajordepressivedisorderevidenceofcerebralamyloidosisandhippocampalatrophy
AT huangshengyao diversityofneurodegenerativepathophysiologyinnondementedpatientswithmajordepressivedisorderevidenceofcerebralamyloidosisandhippocampalatrophy
AT yentzuchen diversityofneurodegenerativepathophysiologyinnondementedpatientswithmajordepressivedisorderevidenceofcerebralamyloidosisandhippocampalatrophy
AT hsiaoingtsung diversityofneurodegenerativepathophysiologyinnondementedpatientswithmajordepressivedisorderevidenceofcerebralamyloidosisandhippocampalatrophy